Novartis To Launch Direct-To-Patient Platform For Cosentyx In U.S. With 55% Discount Starting November 1, 2025

Author: Benzinga Newsdesk | September 29, 2025 09:35am

 

• Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
  
   
• DTP offering to expand to other appropriate products; exploring additional direct-to-employer model to increase access and affordability for cash-paying patients in the US

Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx® (secukinumab) the option to purchase it at a 55% discount off the list price. Cosentyx, Novartis top selling product in the US, is a biologic that is FDA-approved for the treatment of multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa and psoriatic arthritis. It has been studied clinically for more than 17 years and has been used to treat more than 1.8 million patients globally since its launch in 2015.  

Posted In: NVS